AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2060256
Drug: Ibuprofen 200
RxNorm normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 200 mg + Caffeine 100 mg
Trial: 6297368
Drug: Melphalan treatment
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan treatment for mucinous tumours in Stages Ia and Ib
Trial: 6297368
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Melphalan and radiotherapy
Trial: 6297368
Drug: Postoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative treatment for well differentiated, early mucinous tumours in Stage Ia
Trial: 6297368
Drug: Aggressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive treatment for poorly differentiated tumours in Stages I and II
Trial: 11981600
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg methadone
Trial: 11981600
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg methadone
Trial: 8124803
Drug: Dipyridamole echocardiography
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dipyridamole echocardiography (0.84 mg/kg over 10 hours)
Trial: 5472756
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin in a therapeutic dosage
Trial: 31271554
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (3 g/day for 12 weeks)
Trial: 23980090
Drug: Brivanib 800
RxNorm normalized name: Brivanib
DrugBank: Brivanib (DB11958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivanib 800 mg orally once per day plus best supportive care (BSC)
Trial: 20881867
Drug: Blood pressure-lowering
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure-lowering treatments
Trial: 12782900
Drug: Stepped-care treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped-care treatment (counseling and nicotine patch therapy)
Trial: 12782900
Drug: Minimal intervention
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal intervention (no additional treatment)
Trial: 7901058
Drug: Tinidazole 2
RxNorm normalized name: tinidazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole 2 g administered 12 hours before surgery
Trial: 2419945
Drug: iloprost (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iloprost (3 infusions of 5 hours each)
Trial: 31990685
Drug: MIC treatment
RxNorm normalized name: Humatrix Microclysmic Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIC treatment
Trial: 24928796
Drug: Oxybutynin 10
RxNorm normalized name: oxyBUTYnin 10% transdermal gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin 10 mg
Trial: 20937671
Drug: Rituximab 2×1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab 2×1000 mg + MTX
Trial: 20937671
Drug: Rituximab 2×500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab 2×500 mg + MTX
Trial: 18591315
Drug: L-isoleucine
RxNorm normalized name: L-Isoleucine
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-isoleucine
Trial: 18591315
Drug: L-isoleucine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-isoleucine and L-valine
Trial: 18591315
Drug: L-valine
RxNorm normalized name: L-valine
DrugBank: Valine (DB00161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-valine
Trial: 18591315
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of L-isoleucine and L-valine
Trial: 15042546
Drug: Low AGE
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low AGE diet (L-AGE)
Trial: 10518249
Drug: Nandrolone decanoate
RxNorm normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nandrolone decanoate (ND) 200 mg/I.M. weekly for six months
Trial: 7488444
Drug: Alteplase (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase (100 mg over three hours)
Trial: 1785705
Drug: 2.5 ml
RxNorm normalized name: syringe, disposable, 2.5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 ml of a 0.5% bupivacaine solution
Trial: 1785705
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of a 0.125% bupivacaine solution in normal saline
Trial: 6920253
Drug: Pereflat (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pereflat (3 tablets daily for 3 days)
Trial: 6920253
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 tablets daily for 3 days)
Trial: 30591959
Drug: Vaccine alone
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine alone (arm B)
Trial: 30591959
Drug: Vaccine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine plus all-trans-retinoic acid (arm C)
Trial: 26112091
Drug: docetaxel, cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: docetaxel, cisplatin and 5‐fluorouracil induction chemotherapy followed by carboplatin concurrent chemoradiotherapy
Trial: 26112091
Drug: conventional concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional concurrent chemoradiotherapy
Trial: 20603439
Drug: Neoadjuvant cisplatin-based
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant cisplatin-based chemotherapy
Trial: 19710081
Drug: Lower doses
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower doses of xylitol (from toothpaste studies)
Trial: 18318099
Drug: Conventional physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physiotherapy and regular medications
Trial: 1978212
Drug: Sulphasalazine (less
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphasalazine (less than or equal to 3 g/day)
Trial: 226841
Drug: Premarin tablets,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premarin tablets, 1.25 mg per day for 3 weeks
Trial: 19487381
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg orally once daily on a 4 weeks on, 2 weeks off dosing schedule
Trial: 19487381
Drug: Interferon alfa
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa (IFN‐alpha) 9 MU subcutaneously thrice weekly
Trial: 15272670
Drug: Initial solutions
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial solutions based on minimization/maximization of dose to critical structures and targets
Trial: 11384628
Drug: Low-isoflavone diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-isoflavone diet (8 mg/day)
Trial: 11384628
Drug: High-isoflavone diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-isoflavone diet (65 mg/day)
Trial: 11384628
Drug: High-isoflavone diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-isoflavone diet (130 mg/day)
Trial: 8995343
Drug: Daflon 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daflon 500 mg (1000 mg/day) for 4 weeks
Trial: 8425703
Drug: Recombinant interferon
RxNorm normalized name: Recombinant Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon alfa therapy for chronic hepatitis C
Trial: 3300755
Drug: Midazolam 15
RxNorm normalized name: midazolam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 15 mg orally followed at 35 min by i.v. saline
Trial: 28606084
Drug: Cinnamon (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnamon (6 capsules, 3 g daily)
Trial: 28606084
Drug: Wheat flour
RxNorm normalized name: Wheat Flour
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat flour (6 capsules, 2.5 g daily)
Trial: 23683393
Drug: Short-stretch bandages
RxNorm normalized name: Mederma Stretch Mark Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-stretch bandages applied weekly for 2 weeks, followed by a class II elastic stocking for 2 weeks (group A)
Trial: 15894775
Drug: N-acetylcysteine 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine 600 mg orally twice daily for two days
Trial: 10765098
Drug: RPLND +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPLND + 2 cycles of chemotherapy (arm A)
Trial: 10765098
Drug: 3-4 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-4 cycles of primary chemotherapy (arm B)
Trial: 8653870
Drug: Age, hypertension,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age, hypertension, number of antianginal drugs, and ECG changes at rest
Trial: 23916017
Drug: Cognitive Therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Therapy (CT) session
Trial: 23916017
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) session
Trial: 22613054
Drug: Buspirone (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (60 mg/day)
Trial: 17870203
Drug: Rhubarb extract
RxNorm normalized name: Rhubarb extract
DrugBank: Rhubarb (DB10651)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhubarb extract (20 mg kg(‐1) once a day) for 6 weeks
Trial: 14666763
Drug: Qi-supplementing and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qi-supplementing and blood-activating (QSBA) therapy
Trial: 14666763
Drug: Neurotrophic agents
RxNorm normalized name: brain-derived neurotrophic factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurotrophic agents
Trial: 10953421
Drug: Thyroxin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroxin treatment for six months
Trial: 22997787
Drug: Acupoint application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint application combined with routine treatment of western medicine
Trial: 22997787
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment of western medicine
Trial: 11097143
Drug: Gastro-resistant tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastro-resistant tablets (500 mg)
Trial: 11097143
Drug: Prolonged-release tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged-release tablets (1000 mg single dose)
Trial: 11097143
Drug: Oral administrations
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administrations of mesalazine
Trial: 11097143
Drug: Rectal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal administration of mesalazine suppository
Trial: 11097143
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of mesalazine
Trial: 9506005
Drug: Cefodizime (2-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefodizime (2-g intravenous dose)
Trial: 9506005
Drug: Cefpirome (2-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpirome (2-g intravenous dose)
Trial: 8478756
Drug: Aggressive physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive physical therapy for 8 weeks
Trial: 25143491
Drug: e-beam sterilization
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: e-beam sterilization (high dose 17.1 to 21.0 kGy)
Trial: 25143491
Drug: e-beam sterilization
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: e-beam sterilization (low dose 9.2 to 12.2 kGy)
Trial: 18761816
Drug: Atomization inhalation
RxNorm normalized name: Atomic Balm
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomization inhalation of budesonide and terbutaline
Trial: 15908196
Drug: docetaxel 85
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 85 mg/m2 i.v. on day 1 and cisplatin 40 mg/m2 i.v. on days 1 and 2 (arm A)
Trial: 15908196
Drug: cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cisplatin 100 mg/m2 i.v. on day 1 followed by 5‐fluorouracil 1000 mg/m2 in 24 h continuous infusion for 5 d (arm B)
Trial: 1859044
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of oral prednisone 13, 7, and 1 hour before and 50 mg intramuscular diphenhydramine 1 hour before procedures (group I)
Trial: 1859044
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg oral cimetidine one hour before procedure in addition to the other regimen (group II)
Trial: 1859044
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of oral prednisone, 300 mg oral cimetidine, and 25 mg oral ephedrine one hour before procedures (group III)
Trial: 1859044
Drug: Provocative dosing
RxNorm normalized name: OCTINOXATE 0.072 g in 1 g TOPICAL LIPSTICK [EFFET PARFAIT ROUGE AMPLIFIER AMPLIFYING SPF 15 (ROUGE PROVOCATION) - RED]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provocative dosing regimen in a separate group of ten patients whose previous reactions to RCM were life threatening (shock)
Trial: 21332635
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 gel (1- or 2-mg Prostin E2 vaginal gel)
Trial: 21332635
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 tablets (3-mg Prostin E2 vaginal tablets)
Trial: 15921508
Drug: Antipsychotic polypharmacy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic polypharmacy
Trial: 10416052
Drug: Ubiquinone (Q10)
RxNorm normalized name: Ubiquinone
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ubiquinone (Q10) 90 mg/day
Trial: 10416052
Drug: Ubiquinone (Q10)
RxNorm normalized name: Ubiquinone
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ubiquinone (Q10) 180 mg/day
Trial: 7589772
Drug: SCMC‐Lys 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCMC‐Lys 900 mg three times a day (adults) or SCMC‐Lys 270 mg three times a day (children)
Trial: 7589772
Drug: ABX 33
RxNorm normalized name: ABX-EGF
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ABX 33 mg three times a day (adults) or ABX 10 mg four times a day (children)
Trial: 1693042
Drug: Tyrosine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tyrosine (0.3 g/kg) and Tryptophan (0.1 g/kg) for 2 to 17 weeks
Trial: 28091362
Drug: Viaskin Peanut
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viaskin Peanut 100 μg (VP100)
Trial: 28091362
Drug: Viaskin Peanut
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viaskin Peanut 250 μg (VP250)
Trial: 26054865
Drug: Spacer injection
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spacer injection (SpaceOAR system)
Trial: 20979541
Drug: Morning administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning administration of 60 mg dry soy seed extract (glycine max) with 40% total isoflavones, primrose oil, and α‐tocopherol
Trial: 20979541
Drug: Evening administration
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening administration of 60 mg dry soy seed extract (glycine max) with 40% total isoflavones, primrose oil, and α‐tocopherol
Trial: 11586009
Drug: Topical metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical metronidazole 1% vanishing cream
Trial: 2908235
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg D-fenfluramine
Trial: 3322837
Drug: Madopar HBS
RxNorm normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Madopar HBS (200 mg levodopa plus 50 mg benserazide)
Trial: 3322837
Drug: Madopar HBS
RxNorm normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Madopar HBS (3 capsules of 125 mg)
Trial: 3322837
Drug: Standard Madopar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Madopar (2 capsules of 125 mg)
Trial: 31944252
Drug: Talus mobilization
RxNorm normalized name: Malus domestica leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talus mobilization intervention (6 sessions of manual therapy)
Trial: 18491179
Drug: Topical BoNTA
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical BoNTA (CosmeTox) cream (2 U/ml)
Trial: 18491179
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream (without BoNTA)
Trial: 10744129
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg alpha-tocopherol per day
Trial: 10744129
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg alpha-tocopherol per day
Trial: 10744129
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg alpha-tocopherol per day
Trial: 7730690
Drug: Dronabinol 2.5
RxNorm normalized name: dronabinol 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronabinol 2.5 mg twice daily
Trial: 7308334
Drug: OD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OD treatment group (advice and medication for OD)
Trial: 7308334
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment, advised to recheck OD in 2 months)
Trial: 26912555
Drug: Sirolimus (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (3 mg/d; serum target levels of 5‐10 ng/ml) added on to conventional therapy
Trial: 23489975
Drug: Peppermint oil
RxNorm normalized name: Peppermint Oil
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peppermint oil (PO) 182 mg
Trial: 16188178
Drug: Finasteride 1
RxNorm normalized name: finasteride 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride 1 mg daily from 4 weeks before until 48 weeks after hair transplant
Trial: 22719060
Drug: Riociguat 0.5
RxNorm normalized name: riociguat 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riociguat 0.5 mg, 1 mg, or up to 2 mg three times daily (titrated for 8 weeks, followed by 8 weeks at stable dose)
Trial: 20150526
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg daily + Diltiazem 60 mg 3 times daily
Trial: 18689558
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg lycopene/day (placebo)
Trial: 18689558
Drug: 6.5 mg
RxNorm normalized name: menthol 6.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.5 mg lycopene/day
Trial: 18689558
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg lycopene/day
Trial: 18689558
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg lycopene/day
Trial: 10867376
Drug: Allergen specific
RxNorm normalized name: Allergen specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen specific immunotherapy with birch and/or timothy pollen allergen extract
Trial: 10584290
Drug: Optimal pharmacotherapy
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal pharmacotherapy (Control)
Trial: 8803358
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of sexual communication and self-management skills
Trial: 1794369
Drug: Single-dose ornidazole
RxNorm normalized name: ornidazole
DrugBank: Ornidazole (DB13026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose ornidazole
Trial: 25270214
Drug: Xinfeng capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinfeng capsule (XFC), 3 tablets each time, tid, n=70
Trial: 25270214
Drug: Salicylazosulfapyridine (SASP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salicylazosulfapyridine (SASP), 4 pills each time, bid, n=70
Trial: 20518806
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg QD for 12 weeks
Trial: 20518806
Drug: Dapagliflozin 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 20 mg QD for 12 weeks
Trial: 9432341
Drug: RBC400 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC400 + CLAR (Ranitidine bismuth citrate 400 mg bid with clarithromycin 250 mg qid for 14 days)